Since XOMA has said nothing about the new patent I must assume it is not important. Sure seems interesting, though!
Humanized antibodies of the present invention may be administered to patients with a disease having targetable cellular
markers. Such diseases include, but are not limited to, autoimmune diseases such as lupus (including systemic lupus
erythematosus and lupus nephritis), scleroderma diseases (including lichen sclerosis, morphea and lichen planus),
rheumatoid arthritis and the spondylarthropathies, thyroiditis, pemphigus vulgaris, diabetes mellitus type 1, progressive
systemic sclerosis, aplastic anemia, myasthenia gravis, myositis including polymyositis and dermatomyositis, Sjogren's
disease, collagen vascular disease, polyarteritis, inflammatory bowel disease (including Crohn's disease and ulcerative
colitis), multiple sclerosis, psoriasis and primary biliary cirrhosis; other diseases mediated by T cells, such as tissue
transplant rejection and graft versus host disease; diseases caused by viral infections; diseases caused by fungal infections;
diseases caused by parasites; and the like.
Immunoglobulins, antibodies or peptides according to the invention may be administered to a patient either singly or in a
cocktail containing two or more antibodies, other therapeutic agents, compositions, or the like, including, but not limited to,
immunosuppressive agents, potentiators and side-effect relieving agents. Of particular interest are immunosuppressive
agents useful in suppressing allergic or other undesired reactions of a host. Immunosuppressive agents include prednisone,
prednisolone, dexamethasone, cyclophosphamide, cyclosporine, 6-mercaptopurine, methotrexate, azathioprine, and gamma
globulin. All of these agents are administered in generally accepted efficacious dose ranges such as those disclosed in the
Physician's Desk Reference, 41st Ed. (1987). In addition to immunosuppressive agents, other compounds such as an
angiogenesis inhibitor may be administered with the anti-pan T immunoglobin. See Peacock, et al., Arthritis and Rheum. 35
(Suppl.) , Abstract, No. B141 (September 1992).
Anti-pan T cell immunoglobulins may be formulated into various preparations such as injectable and topical forms.
Parenteral formulations are preferred for use in the invention, most preferred is intramuscular (i.m.) or intravenous (i.v.)
administration. The formulations containing therapeutically effective amounts of anti-pan T cell antibodies are either sterile
liquid solutions, liquid suspensions or lyophilized versions and optionally contain stabilizers or excipients. Lyophilized
compositions are reconstituted with suitable diluents, e.g., water for injection, saline, 0.3% glycine and the like, at a level of
from about .01 mg/kg of host body weight to about 10 mg/kg or more of host body weight. |
